Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The economic value of a quadrivalent versus trivalent influenza vaccine.

Lee BY, Bartsch SM, Willig AM.

Vaccine. 2012 Dec 14;30(52):7443-6. doi: 10.1016/j.vaccine.2012.10.025. Epub 2012 Oct 19. Erratum in: Vaccine. 2013 May 7;31(20):2477-9.

2.

Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.

You JH, Ming WK, Chan PK.

Hum Vaccin Immunother. 2015;11(3):564-71. doi: 10.1080/21645515.2015.1011016.

3.

Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.

Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.

BMC Infect Dis. 2015 Oct 27;15:465. doi: 10.1186/s12879-015-1193-4.

4.

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.

You JH, Ming WK, Chan PK.

BMC Infect Dis. 2014 Nov 25;14:618. doi: 10.1186/s12879-014-0618-9.

5.

Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.

de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.

Value Health. 2016 Dec;19(8):964-975. doi: 10.1016/j.jval.2016.05.012. Epub 2016 Jul 15.

6.

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.

Jamotte A, Clay E, Macabeo B, Caicedo A, Lopez JG, Bricks L, Romero Prada M, Marrugo R, Alfonso P, Moreno Arévalo B, Franco D, Garcia Diaz L, Isaza de Molto Y.

Hum Vaccin Immunother. 2017 Apr 3;13(4):877-888. doi: 10.1080/21645515.2016.1256928. Epub 2017 Jan 24.

7.

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.

BMC Infect Dis. 2013 May 20;13:224. doi: 10.1186/1471-2334-13-224.

8.

4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.

Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R.

BMC Infect Dis. 2014 Jul 3;14:365. doi: 10.1186/1471-2334-14-365.

9.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.

Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.

Vaccine. 2013 Nov 12;31(47):5572-8. doi: 10.1016/j.vaccine.2013.08.069. Epub 2013 Sep 7.

PMID:
24016810
10.

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.

Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

Vaccine. 2014 Mar 14;32(13):1480-7. doi: 10.1016/j.vaccine.2014.01.022. Epub 2014 Jan 28.

11.

Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.

Meier G, Gregg M, Poulsen Nautrup B.

J Med Econ. 2015;18(9):746-61. doi: 10.3111/13696998.2015.1044456. Epub 2015 Jun 8.

PMID:
25903831
12.

Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R.

Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:39-46. doi: 10.1111/irv.12318.

13.

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.

Pediatr Infect Dis J. 2014 Dec;33(12):1262-9. doi: 10.1097/INF.0000000000000463.

PMID:
25386965
14.

A systematic review of the health economic consequences of quadrivalent influenza vaccination.

de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ.

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265. doi: 10.1080/14737167.2017.1343145. Epub 2017 Jun 28. Review.

PMID:
28613092
15.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
16.

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.

Jain VK, Chandrasekaran V, Wang L, Li P, Liu A, Innis BL.

BMC Infect Dis. 2014 Mar 10;14:133. doi: 10.1186/1471-2334-14-133.

17.

A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.

Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E.

Infect Dis Ther. 2015 Dec;4(4):459-87. doi: 10.1007/s40121-015-0076-8. Epub 2015 Sep 9. Erratum in: Infect Dis Ther. 2015 Dec;4(4):489-90.

18.

Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.

Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.

Pediatr Infect Dis J. 2014 Jun;33(6):630-6. doi: 10.1097/INF.0000000000000254.

PMID:
24445833
19.

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG.

Hum Vaccin Immunother. 2017 Apr 3;13(4):867-876. doi: 10.1080/21645515.2016.1251537. Epub 2016 Nov 18. Review.

20.

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.

Reed C, Meltzer MI, Finelli L, Fiore A.

Vaccine. 2012 Mar 2;30(11):1993-8. doi: 10.1016/j.vaccine.2011.12.098. Epub 2012 Jan 5.

PMID:
22226861

Supplemental Content

Support Center